Understanding the mechanisms of SGLT2 inhibition in heart failure and diabetes
Video navigation menu
- EMPA-REG Outcome trial: set up and expectations 0:27
- No effect on MI and stroke was seen with empagliflozin, but there were positive surprises 1:37
- Speculations on the mechanisms underlying the clniical benefits of SGLT2 inhibition 3:23
- Effects of empagliflozin on kidney function 6:28
- The ketone hypothesis 7:03
- Other evidence on hemodynamic effects of SGLT2 inhibition, and an early hypothesis on the origin of the CV benefits 7:40
This lecture by prof Naveed Sattar was part of a CME accredited symposium: Contemporary management of a patient with Heart Failure and diabetes: Implications from recent trials?' held at ESC Heart Failure 2018 in Vienna, Austria.
Naveed Sattar, MD is Professor of Metabolic Medicine, University of Glasgow. He is an academic (active clinically) experienced in biomarker studies/trials investigating the causes, prevention and management of diabetes, obesity and heart disease.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim.